Turnstone Biologics Q4 EPS $(0.73) Beats $(0.86) Estimate
Portfolio Pulse from Benzinga Newsdesk
Turnstone Biologics (NASDAQ:TSBX) reported a Q4 EPS loss of $(0.73), surpassing the analyst consensus estimate of $(0.86) by 15.12%.
March 21, 2024 | 9:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Turnstone Biologics reported a smaller than expected Q4 loss, beating analyst estimates.
Beating earnings estimates typically leads to positive investor sentiment and can result in a short-term increase in stock price. The significant beat of 15.12% suggests operational efficiency or cost management that was better than what analysts anticipated.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100